Literature DB >> 23347126

Clozapine in severe conduct disorder.

Eduardo H Teixeira1, Eloisa V Celeri, Antonio C A Jacintho, Paulo Dalgalarrondo.   

Abstract

METHOD: An open, naturalistic observational study design was used, in which a sample of seven boys between 10 and 14 years of age was assessed over 26 weeks.
RESULTS: The subjects were all diagnosed with conduct disorder (CD) and exhibited high levels of aggression that were refractory to psychosocial approaches (parent counseling, school counseling, and psychotherapy) and to more than three pharmacological treatments. Levels of aggression, side effects, and hematological parameters were evaluated weekly. Clinical response was evaluated using the standardized instruments Clinical Global Impressions (CGI) and Child Behavior Check List (CBCL) 6-18 before starting medication and after 26 weeks.
CONCLUSION: We observed good tolerability of clozapine in doses from 100 to 600 mg/day with no significant side effects or hematological changes. The CGI and CBCL 6-18 scales indicated that clozapine led to a marked control of symptoms.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23347126     DOI: 10.1089/cap.2011.0148

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  3 in total

Review 1.  Atypical antipsychotics for disruptive behaviour disorders in children and youths.

Authors:  Jik H Loy; Sally N Merry; Sarah E Hetrick; Karolina Stasiak
Journal:  Cochrane Database Syst Rev       Date:  2017-08-09

2.  Clozapine Use in Adolescents.

Authors:  Samir Kumar Praharaj
Journal:  Indian J Psychol Med       Date:  2017 Jan-Feb

3.  Clozapine in the Treatment of Aggression in Conduct Disorder in Children and Adolescents: A Randomized, Double-blind, Controlled Trial.

Authors:  Myrthala Juárez-Treviño; Antonio Costilla Esquivel; Lilia Marytza Leal Isida; Dionicio Ángel Galarza Delgado; Manuel E de la O Cavazos; Lourdes Garza Ocañas; Rosalinda Sepúlveda Sepúlveda
Journal:  Clin Psychopharmacol Neurosci       Date:  2019-02-28       Impact factor: 2.582

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.